Encorafenib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 50mg, 75 mg
Reference Brands: Braftovi (USA/EU)
Category:
Oncology Cancer Care
Encorafenib is a targeted anticancer medicine classified as a BRAF kinase inhibitor. It works by blocking the activity of the mutated BRAF V600 protein, which promotes abnormal cell growth in certain cancers. Marketed under the brand name Braftovi, it is available as oral hard capsules in 50 mg and 75 mg strengths. It is mainly used for the treatment of melanoma and metastatic colorectal cancer with a BRAF V600 mutation, often in combination with other targeted therapies such as binimetinib.
Encorafenib is available in Capsules
and strengths such as 50mg, 75 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Encorafenib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Encorafenib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing